ArticleAntibiotics (Basel, Switzerland)2026
Long-Term Trends in Antimicrobial Resistance Among Gram-Negative Clinical Isolates at Mubarak Al-Kabeer Hospital, Kuwait (2007-2022).
Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the long-term trends in antimicrobial resistance (AMR) among major Gram-negative pathogens including
methodsThe antimicrobial resistance data for 39,200 non-duplicate Gram-negative isolates were collected from the Hospital Laboratory Information System (LIS). Retrospectively antibiotic susceptibility data were interpreted according to Clinical and Laboratory Standards Institute (CLSI) breakpoints with intermediate results classified as resistant. Logistic regression was applied to assess temporal trends in resistance for the following antibiotic cefotaxime, ceftazidime, ciprofloxacin, meropenem and imipenem. False discovery rate (FDR) correction was performed for multiple comparisons.
resultsThird-generation cephalosporin resistance increased significantly, from 27% to 60% in
conclusionsFrom 2007 to 2022, increasing resistance among major Gram-negative pathogens was observed, with cefotaxime resistance rising from 27% in 2007 to 60% in 2022 in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.